PF4 and COVID-19: This presents the possibility that patients were VITT were pre-sensitized by an earlier infection with a PF4-binding virus, and that a large number of COVID-19 vaccinees would now be primed for an acute secondary immune response and potentially thrombosis in case of future exposure to PF4-binding vectors.